Shockwave IVL and innovation continue to go hand in hand as we deliver new advancements to address severe, complex calcium meeting physician and patient needs alike. Thank you, Dr. @rwyeh for presenting the FORWARD CAD 30-day results at #TCT2026# today. FORWARD CAD met its performance goals, demonstrating high technical success (93.6%) and a high rate of freedom from MACE through 30 days (93.4%) in a highly stenotic lesion cohort. These data from the prospective, multicenter, single-arm, IDE study of the Shockwave Javelin #CoronaryIVL# catheter show how the robust #ShockwaveIVL# portfolio is expanding beyond balloon-based therapies for the coronaries. Read the press release: CAUTION - Investigational device. Limited by US law to investigational use.